{"classes":[{"categories":[{"measurements":[{"comment":"None of the analyzed samples were positive for anti-CP-751,871 antibodies, as suggested by a titer measurement of less than 3.32.","groupId":"OG000","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"groups":[{"description":"CP-751,871 0.025, 0.05, 0.1, 0.2, 0.4, 0.8, 1.5, 3 and 6 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks); CP-751,871 10 and 20 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG000","title":"CP-751,871 0.025-20 mg/kg"}],"paramType":"NUMBER","populationDescription":"All treated participants with HAHA samples collected at time points when circulating CP-751,871 concentrations were below the lower limit of quantification.","reportingStatus":"POSTED","timeFrame":"30 minutes predose in Cycle 1 and subsequent cycles, end of study visit (Days 30 and 60) for dose levels below 0.8 mg/kg; 30 minutes predose in Cycle 1 and last scheduled follow-up visit for dose levels greater than or equal to 0.8 mg/kg","title":"Human Anti-human Antibody (HAHA) Response to CP-751,871","type":"SECONDARY"}